| |
|
|
|
Nymox Pharmaceutical Corporation  
|
|
2.65 0 (0%) |
08-17 16:00 |
|
Open: |
2.59 |
Pre close: |
2.65 |
Target:
|
3.63
|
|
High: |
2.69 |
Low: |
2.58 |
Resistance:
|
3.11
3.47
|
|
Volume: |
139,205 |
Market Cap: |
170M |
Support:
|
2.53
2.10
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
2.82
 |
MACD |
MACD(12,26):
|
-0.16 |
|
MA(20): |
3.11 |
Signal(12,26,9): |
-0.11 |
|
MA(100): |
3.65 |
Stochastic Oscillator |
%K(14,3):
|
17.50  |
|
MA(250): |
3.61 |
%D(3): |
15.76 |
|
Average Volume(K) |
3-Month: |
11347
|
52-Week |
High:
|
4.60 |
|
10-Days: |
13366 |
Low: |
2.53 |
|
RSI |
RSI(14):
|
22.59 |
Change(%): |
-21.1 |
|
Financials, Statistics and Valuation |
|
EPS |
0.000 |
Return on Equity (ttm) |
1199.9 |
Shares Out. (M) |
57.84 |
|
EPS Est. Current Year |
-0.200 |
Return on Assets (ttm) |
-998.0 |
Shares Float (M) |
54.67 |
|
EPS Est. Next Year |
-0.570 |
PEG Ratio |
0.00 |
% Held by Insiders |
5.50 |
|
EPS Est. Next Quarter |
0.000 |
Qtrly Rev. Growth |
94.9 |
% Held by Institutions |
6.10 |
|
Forward EPS |
1.#IO |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
2095 |
|
Book Value (p.s.) |
27420.811 |
EBITDA (p.s.) |
0.000 |
P/E |
0.00 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
0.00 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-7.30 |
P/S |
0.00 |
|
Operating Margin |
-4406.38 |
Levered Free Cash Flow
(M) |
-2.35 |
P/CF |
-21.00 |
|
|
|
|
|
|
